Consistently, the French Intergroup on Myeloproliferative Neoplasms (FIM) reported a decrease in the JAK2 allele burden of more than 50% in more than half of the patients, while the CALR remained stable [43]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.